Key points are not available for this paper at this time.
Background: People with HIV (PWH) on integrase inhibitor-based regimens may be at risk of excess weight gain, but it is unclear if this risk is consistent across settings. We assessed weight change over 48 weeks among PWH who were transitioned to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD). Design: We conducted a prospective cohort study at public-sector HIV clinics in Uganda and South Africa. Methods: Eligible participants were adults who were transitioned to TLD. Weight was measured at enrollment, 24-, and 48-weeks post TLD transition. Our outcomes were weight change, change in waist circumference, and clinically significant weight gain, defined as ≥10% increase in weight from baseline, over 48 weeks. We used linear mixed-effects regression models, adjusted for demographic factors, to estimate weight gain and identify risk factors. Results: Weight data were available for 428 participants in Uganda and 367 in South Africa. The mean weight change was 0.6 kg 95% CI: 0.1–1.0 in Uganda and 2.9 kg 2.3–3.4 in South Africa ( P < 0.001). The mean change in waist circumference was 0.8 cm 95% CI: 0.0–1.5) in Uganda and 2.3 cm 95% CI: 1.4–3.2 in South Africa ( P = 0.012). Clinically significant weight gain occurred in 9.8% 7.0–12.6 of participants in Uganda and 18.0% 14.1–21.9 in South Africa ( P < 0.001). After adjustment, PWH gained significantly less weight in Uganda than in South Africa. Conclusions: PWH in South Africa experienced significantly greater weight gain and increases in waist circumference compared to Uganda. Strategies to address weight gain in PWH should be carefully considered and may vary by region.
Migisha et al. (Tue,) studied this question.